Effectiveness of Zingiber officinale to reduce inflammation in community acquired pneumonia

INTERVENTION: Experimental Drug,No Intervention Drug In treatment group, the patients received oral Z. officinale capsule 300 mg daily for five days as well as CAP standard therapy. ,In the control group, the patient received CAP standard therapy Treatment group,Control group CONDITION: community acquired pneumonia; Zingiber officinale var rubrum; inflammatory marker; length of hospitalization met the diagnostic criteria of CAP confirmed by pneumonia symptoms such as cough, change/purulence of sputum color, fever, or breathlessness had pneumonia sign by chest X‐ray (infiltrate of pneumonia). ; community acquired pneumonia; Zingiber officinale var rubrum; inflammatory marker; length of hospitalization PRIMARY OUTCOME: IL‐6 5 days after intervention IL‐6 Human ELISA kit (DE2132) quantitative assay,PCT 5 days after intervention PCT Human ELISA kit (E‐EL‐H1492) quantitative assay,NLR 5 days after intervention leukocyte diffcount examination by using a blood smear and be counted manually (Neubauer) SECONDARY OUTCOME: Length of stay 5 days after intervention Total days from admission until discharge date INCLUSION CRITERIA: 1. met the diagnostic criteria of CAP 2. confirmed by pneumonia symptoms such as cough, change/purulence of sputum color, fever, or breathlessness 3. had pneumonia sign by chest X‐ray (infiltrate of pneumonia).